Addex stock tanks after lead drug flops in Phase II epilepsy trial [Yahoo! Finance]
Cerevel Therapeutics Holdings, Inc. (CERE)
Company Research
Source: Yahoo! Finance
Following the release of the Phase II top-line results, the Swiss company's stock was down by 53.3% at the market close on 29 April compared to the market close on the previous day. According to Yahoo Finance , Addex's market cap stands at $8.8m. The placebo-controlled Phase II trial (NCT04836559) evaluated ADX71149 (JNJ-40411813) as an adjunct therapy in 110 patients with epilepsy. The study failed to achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count. Addex did not provide additional information regarding the future of drug development. However, the company's chief medical officer, Roger Mills, added: “We will provide details on data from the full study when this analysis is completed and will work with our partner to determine the next steps for the ADX71149 program.” ADX71149 is a positive allosteric modulator (PAM) of metabotropic glutamate receptor-2 (mGlu2 receptor), which plays a key role in seizure initiation
Show less
Read more
Impact Snapshot
Event Time:
CERE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERE alerts
High impacting Cerevel Therapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CERE
News
- BREAKING CEREVEL INVESTIGATION: BFA Law Is Investigating the $45 Per CERE (Nasdaq) Share Offer by AbbVie, Contact the Firm for DetailsGlobeNewswire
- 1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165? [Yahoo! Finance]Yahoo! Finance
- NOTICE OF INVESTIGATION: Kaskela Law LLC Announces Shareholder Investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) and Encourages Investors to Contact the FirmPR Newswire
- INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerevel Therapeutics and AbbVie for Unfair ProcessGlobeNewswire
- ACQUISITION ALERT BFA LLP Notifies Cerevel Therapeutics Shareholders of an Investigation into the Merger with AbbVieAccesswire
CERE
Earnings
- 5/8/24 - Miss
CERE
Sec Filings
- 5/14/24 - Form 4
- 5/10/24 - Form 144
- 5/10/24 - Form SC
- CERE's page on the SEC website